Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R.

Xiao H, Xiao Q, Zhang K, Zuo X, Shrestha UK.

Ann Hematol. 2010 Apr;89(4):399-404. doi: 10.1007/s00277-009-0831-6.

PMID:
19756599
2.
4.

Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.

Tang XQ, Bi H, Feng JQ, Cao JG.

Acta Pharmacol Sin. 2005 Aug;26(8):1009-16.

6.

Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.

Chen P, Li J, Jiang HG, Lan T, Chen YC.

Tumour Biol. 2015 May;36(5):3591-9. doi: 10.1007/s13277-014-2996-4.

PMID:
25542235
7.

[Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].

Xiong T, Wei H, Chen X, Xiao H.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Jun;31(3):312-6. doi: 10.3760/cma.j.issn.1003-9406.2014.03.012. Chinese.

PMID:
24928009
8.

[The study on reversing mechanism of multidrug resistance of K562/A02 cell line by curcumin and erythromycin].

Chang HY, Pan KL, Ma FC, Jiao XY, Zhu HF, Liu JH, Huang Y, Cao YH.

Zhonghua Xue Ye Xue Za Zhi. 2006 Apr;27(4):254-8. Chinese.

PMID:
16875558
9.

Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.

Choi BH, Kim CG, Lim Y, Shin SY, Lee YH.

Cancer Lett. 2008 Jan 18;259(1):111-8.

PMID:
18006147
10.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.

Cancer Res. 2009 Dec 15;69(24):9367-75. doi: 10.1158/0008-5472.CAN-09-2616.

11.

Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.

Siddique MA, Nakanishi K, Taniguchi T, Grompe M, D'Andrea AD.

Exp Hematol. 2001 Dec;29(12):1448-55.

PMID:
11750104
12.

Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.

Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE.

Cancer Biol Ther. 2007 May;6(5):654-60.

PMID:
17387268
13.
14.

Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.

Landais I, Hiddingh S, McCarroll M, Yang C, Sun A, Turker MS, Snyder JP, Hoatlin ME.

Mol Cancer. 2009 Dec 31;8:133. doi: 10.1186/1476-4598-8-133.

15.

Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.

Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.

Life Sci. 2008 Nov 21;83(21-22):700-8. doi: 10.1016/j.lfs.2008.09.009.

PMID:
18845169
16.

Synthesis of curcumin mimics with multidrug resistance reversal activities.

Um Y, Cho S, Woo HB, Kim YK, Kim H, Ham J, Kim SN, Ahn CM, Lee S.

Bioorg Med Chem. 2008 Apr 1;16(7):3608-15. doi: 10.1016/j.bmc.2008.02.012.

PMID:
18295490
17.

FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.

Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, Willers H.

Cancer Lett. 2011 Jun 1;305(1):86-93. doi: 10.1016/j.canlet.2011.02.030.

PMID:
21414716
18.

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.

Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD.

Mol Cancer Ther. 2006 Apr;5(4):952-61.

19.
20.

Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R).

Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S.

Cancer Biol Ther. 2008 Jul;7(7):1024-32.

PMID:
18414057
Items per page

Supplemental Content

Support Center